Similarly, HER2-targeted therapy may be applied to other cancer types analogous to breast cancer because ERBB2/HER2, which can be amplified in breast cancer, is also mutated and/or amplified in subsets of glioblastoma and gastric, serous endometrial, bladder and lung cancers (Cancer Genome Atlas Research et al., 2013). This evidence concerns the gene ERBB2 and breast carcinoma.